Clinical trials: Mild Alzheimer Disease
Dementia, Dementia, Vascular
Feasibility of the SmartPrompt for Improving Everyday Function in Dementia
Difficulty completing everyday tasks is a primary reason for the high cost of care, loss of caregiver paid hours, and general caregiver burden associated with dementia.
- Conditions
- Dementia, Dementia, Vascular, Dementia Alzheimers, Dementia, Mixed
- Trial name
- SmartPrompt (NCT04313582)
- Testing
- SmartPrompt smartphone application
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Temple University
Cognitive Decline, Mild, Alzheimer Disease
Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD)
The goal of this placebo-controlled double-blind Phase 2 clinical trial is to test in people with early Alzheimer's Disease. The main questions it aims to answer are: Does treatment with fasudil, a ROCK-inhibitor, lead to…
- Trial name
- FEAD (NCT06362707)
- Testing
- Fasudil
- Where
- 6 sites in Norway
- Volunteers
- 200 people
- Sponsor
- Helse Stavanger HF
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
A Clinical Study Evaluating the Diagnostic Performance and Safety of PET for the Deposition of Aβ Plaques in the Brain of Participants With Normal Cognitive Function, MCI and AD Using [18F]Fluorbetazine Injection
A multicenter phase III clinical study evaluating the diagnostic performance and safety of PET for the deposition of Aβ plaques in the brain of participants with normal cognitive function, MCI and AD using [18F]Fluorbetazine…
- Trial name
- NCT07764679
- Testing
- [18F]Fluorbetazine injection
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- HTA Co., Ltd.
Mild Cognitive Impairment, Healthy Aging
SHARE(D) Stage II: Alzheimer's Risk Disclosure Protocol Piloting
The goal of this study is to test efficacy and safety of person-centered, culturally-informed protocols for disclosure of different combinations of Alzheimer's dementia risk factors.
- Trial name
- SHARE(D) (NCT04309500)
- Testing
- Personalized DAT Risk Disclosure Protocol
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Alzheimer's Disease，Mild Cognitive Impairment
Cohort Study on Cognitive Decline in Elderly
Alzheimer's Disease (AD) prevention and control currently face severe challenges, with limited treatment options and effectiveness available. Once the disease progresses to the AD stage, it is essentially irreversible.
- Trial name
- NCT07093892
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Peking University Third Hospital
Alzheimer's Disease
Evaluating Liraglutide in Alzheimer's Disease
This is a 12-month, multicentre randomised double-blind placebo-controlled Phase IIb study in patients with mild Alzheimer's dementia (AD). Patients will be randomised on a 1:1 ratio to receive liraglutide or matching placebo.
- Trial name
- ELAD (NCT01843075)
- Testing
- Liraglutide
- Where
- United Kingdom
- Volunteers
- 204 people
- Sponsor
- Imperial College London
Alzheimer's Disease, Mild Cognitive Impairment
Wisconsin Brain Donor Program
The Wisconsin Brain Donor Program (WBDP) stores brain and other tissues/samples (e.g. blood and CSF) from deceased individuals who have participated in longitudinal research studies, as well as other select participants.
- Trial name
- WBDP (NCT00585572)
- Where
- United States
- Volunteers
- 9,999 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Neurodegenerative Disease, Mild Cognitive Impairmen
Clinical Cohort of Memory Disorders
This observational study is designed as a multicenter clinical cohort to collect and bank blood specimens linked to clinical and brain imaging data for biomarker discovery and validation in memory disorders.
- Conditions
- Neurodegenerative Disease, Mild Cognitive Impairmen, Dementia, Alzheimer Disease
- Trial name
- NCT07880275
- Where
- South Korea
- Volunteers
- 1,550 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Alzheimer Disease, Mild Cognitive Impairment
Study to Understand Novel Biomarkers in Researching Dementia
The purpose of this study is to determine the relationships between amyloid, tau, and neurodegeneration biomarkers in the blood and the presence of Alzheimer's disease (AD) pathology, clinical cognitive decline, and diagnosis.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia
- Trial name
- SUNBIRD (NCT06547099)
- Testing
- Clinical tau PET, Clinical amyloid test, Research blood collection
- Where
- United States
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Mild Cognitive Impairment, Alzheimer's Disease
BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM)
Mild Cognitive Impairment (MCI) represents a group of persons who are at risk of incident dementia in the near-term. Persons with MCI who have deficits in short-term recall (amnestic MCI) are at significant risk of incident…
- Trial name
- BDPP (NCT02502253)
- Testing
- grape seed polyphenolic extract, resveratrol
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Johns Hopkins University
Mild Cognitive Impairment, Alzheimer Disease
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Dementia
The purpose of this study is to investigate whether a blood pressure medication, spironolactone, can be tolerated by older African American adults that have memory and thinking problems, also called mild cognitive impairment…
- Trial name
- STAND (NCT04522739)
- Testing
- Spironolactone
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Emory University
Alzheimer Disease
Exploratory Study of Low-Dose Whole-Brain Radiation Therapy With HeLaXON 1X in Patients With Mild Alzheimer's Disease Dementia
This randomized, sham-controlled, exploratory clinical trial will evaluate the efficacy and safety of HeLaXON, an investigational low-dose radiation therapy device, in patients with mild Alzheimer's disease dementia.
- Trial name
- LDRT-AD-03 (NCT07863011)
- Testing
- HeLaXON 1X Low-Dose Radiation Therapy
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- ReadyCure Inc.
Alzheimer Disease, Mild Cognitive Impairment
Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA)
Apheleia-001 is a prescreener that aims to identify and characterize participants with reported cognitive impairment using demographic information, clinical history, brief cognitive assessments, and blood-based biomarkers to…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Memory Loss, Memory Disorders
- Trial name
- NCT05364307
- Testing
- Prescreener database
- Where
- 19 sites in United States, Canada
- Volunteers
- 1,555 people
- Sponsor
- Global Alzheimer's Platform Foundation
Alzheimer Disease
Blood Brain Barrier Opening in Alzheimer' Disease
In Alzheimer's disease (AD) an imbalance between the production and clearance of the ß-amyloid peptide is hypothesized as the driving event of the disease.
- Trial name
- BOREAL1 (NCT03119961)
- Testing
- SONOCLOUD®
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Mild Cognitive Impairment, Alzheimer Disease
Causal Effect of Coenzyme Q10 Nutrition and Cognitive Dysfunction in the Metabolic Storm (Hyperglycemia and Sarcopenia) and Brain-derived Neurotrophic Factor
The aim of the study is to investigate the effects of coenzyme Q10 supplementation (150 mg twice daily; 300 mg/day for 12 weeks) on coenzyme Q10 status, glucose parameters, BDNF, myokines, and cognitive function in patients with…
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Hyperglycemia, Pre-sarcopenia
- Trial name
- NCT06040905
- Testing
- Coenzyme Q10
- Where
- Taiwan
- Volunteers
- 51 people
- Sponsor
- Chung Shan Medical University
Dementia, Mild Cognitive Impairment
In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment
This study aims to develop and evaluate new in-home supportive technology that is designed to alleviate anxiety, burden, and loneliness in spousal and familial caregivers of individuals with Alzheimer's disease, other dementias…
- Conditions
- Dementia, Mild Cognitive Impairment, Alzheimer Disease
- Trial name
- NCT04206670
- Testing
- In-Home Technology System and Questionnaires, Waiting Control In-Home Technology System and Questionnaires
- Where
- United States
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- University of California, Berkeley
Alzheimer's Disease
Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms
The purpose of this trial is to assess the efficacy and safety of S47445 versus placebo in patients with Alzheimer's disease at mild to moderate stages with depressive symptoms.
- Trial name
- NCT02626572
- Testing
- S47445 5mg, S47445 15mg, S47445 50mg
- Where
- 78 sites in Brazil, Bulgaria and 10 more
- Volunteers
- 500 people
- Sponsor
- Institut de Recherches Internationales Servier
Alzheimer Disease
Clinical Trial to Explore the the Amyloid Beta Draining Effect of Thiethylperazine (TEP) in Subjects With Newly Diagnosed Early-to-mild Dementia Due to Alzheimer's Disease (AD) in Comparison to Healthy Volunteers
This proof-of-mechanism clinical trial study will test the efficacy and safety of thiethylperazine (TEP) in subjects with early onset of Alzheimer's Disease (AD).
- Trial name
- drainAD (NCT03417986)
- Testing
- TEP
- Where
- 2 sites in Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Immungenetics AG
Healthy, Subjective Cognitive Decline (SCD)
Sleep Stimulation to Enhance Waste Clearance in the Brain
This study aims to examine whether multi-night closed-loop auditory stimulation (CLAS) during sleep can enhance waste clearance and memory consolidation in healthy adults and older adults with subjective cognitive decline or mild…
- Conditions
- Healthy, Subjective Cognitive Decline (SCD), Mild Cognitive Impairment (MCI), Alzheimer Disease (AD)
- Trial name
- NCT07051239
- Testing
- Closed-loop acoustic stimulation
- Where
- Belgium
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Erasme University Hospital
Alzheimer's Disease
Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease
The study is a randomized, parallel, 4-dose design in subjects with mild-to-moderate Alzheimer's Disease. Subjects will be randomized to one of 4 doses of T3D-959.
- Trial name
- NCT02560753
- Testing
- T3D-959
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- T3D Therapeutics, Inc.